Video
Author(s):
Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.
Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.
Navitoclax can induce thrombocytopenia, which can be a problem for patients with advanced myelofibrosis who don't have normal platelet levels. However, in a phase II trial, investigators were able to manage thrombocytopenia with a slow ramp-up of navitoclax and an individualized dose based on the patient’s platelet level, says Garcia. Alternatively, the dose of navitoclax could have been reduced.
With this approach, no evidence of clinically significant bleeding was observed. Patients who remained on the combination by weeks 6 to 8 experienced thrombocytopenia, but this was expected and consistent with the use of ruxolitinib (Jakafi), concludes Garcia.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512